# Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors

> **NCT01324258** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 19 (actual)

## Conditions studied

- Solid Tumours

## Interventions

- **DRUG:** GSK1120212
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT01324258
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-24
- **Primary completion:** 2013-07-08
- **Final completion:** 2013-07-08
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2017-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01324258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01324258, "Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01324258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*